MRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

ABSTRACT: The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has been derived from BT474 and was cultured to be resistant as well. Based on RNA-Seq data, we performed differential expression analyses on these breast cancer cell lines with and without trastuzumab treatment. In detail, five separate tests were performed, namely resistant cells vs. wild type, i.e. HCC1954 and BTR50 vs. BT474, respectively, and untreated vs. drug treated cells. The significant genes of the first two tests should contribute to resistance. The significant genes of the test BT474 vs. i

ORGANISM(S): Homo sapiens

SUBMITTER: Silvia von der Heyde 

PROVIDER: E-GEOD-55005 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress